Antifungal susceptibilities of 113 clinical isolates of Cryptococcus neoformans and candida SP to the new antifungal albaconazole (UR9825) respect to voriconazole and fluconazole

The goal of this study was to assess the Minimal Inhibitory Concentrations (MICs) to the new azoles Albaconazole (ALBA)(1) and Voriconazole (VNZ) in 113 human clinical isolates of Cryptococcus neoformans (N=33) and Candida sp (N=80). Among these 49% were included because of resistance to fluconazole. Testing was done with a broth microdilution method, according to the NCCLS recommendations (M27-A). Eight of the 38 fluconazole resistant isolates presented values 3 4 for VNZ and 5 for ALBA. For both azoles the species with lower geometric mean were Candida dubliniensis and C tropicalis and the high values were for C glabrata. None of the C krusei fluconazole resistant isolates (N=23) showed MICs >0.25 mug/ml for ALBA and 2 of these isolates presented MICs of I mug/ml for VNZ. All the C. neoformans isolates showed MICs less than or equal to 0.5 mug/ml for the two azoles, including two fluconazole resistant strains. Albaconazole and Voriconazole are two new antifungals very active against pathogenic yeasts, including most of fluconazole resistant ones.